Mr. Philip Yeo is the Chairman of the Board of Directors for A-Bio Pharma Pte Ltd.  Mr Yeo is currently the Special Advisor for Economic Development (Prime Minister's Office), Senior Advisor for Science and Technology (Ministry of Trade & Industry) and Chairman of the Standards, Productivity and Innovation Board (SPRING) in Singapore .  He was formerly the Chairman of the Agency for Science, Technology and Research (A*STAR), the Economic Development Board (EDB) and the National Computer Board (NCB).  Prior to these appointments, Mr Yeo served in the Ministry of Defence where he held several appointments including the appointment of Permanent Secretary for Defence for logistics, technology research & development and defence industries.   Mr. Yeo is the recipient of many national and international awards from industries, institutions and governments, and was conferred an honorary doctorate in Engineering from the University of Toronto and an honorary degree of Doctor of Medicine by the Karolinska Institute.  In addition, Mr. Yeo is a board member in many listed companies.

 

 

Mr. Clateo Castellini holds a BA in Economics from Bocconi University in Milano, Italy and completed the Advanced Management Program at the Harvard Business School. He started his career in Lepetit , an Italian Pharmaceutical company, which was later acquired by Dow Chemical. At Lepetit and Dow he worked on various assignments in Europe, South America and US. In 1978 Mr. Castellini joined Becton, Dickinson & Company and served in various postings around the world and later was posted to the Corporate Headquarter in New Jersey. In 1994 he became Chairman, President and CEO of Becton, Dickinson & Company and retired in 2002. He is currently on the board of Quintiles Transnational Corp. and A-Bio Pharma.

 

 

Ms. Chu Swee Yeok is the Chief Executive Officer of Bio*One Capital Pte Ltd, an investment management company of the Singapore Economic Development Board (SEDB).  Ms Chu has more than 20 years of experience in investment and technology promotion, strategic planning and business development in biomedical sciences.  She led the establishment of Biomedical Sciences Investment Fund, SEDB’s largest investment fund of US$600 million in late 2000.  Together with three other funds, Bio*One Capital has more than 60 portfolio companies globally.  Ms Chu holds several board directorship responsibilities, including S*BIO Pte Ltd, Merlion Pharmaceuticals Pte Ltd, CombinatoRx Singapore, Lonza Biologics Tuas Pte Ltd, Novartis Institute for Tropical Diseases and Exploit Technologies Pte Ltd.

 

 

Mr. John Nine holds a BS degree in pharmacy and an honorary science doctorate of pharmacy from Purdue University.  He received an honorary science doctorate of pharmacy from Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University and an honorary doctorate of Humane Letters from Florida A & M University. Mr. Nine joined Schering-Plough in 1975 as vice president - pharmaceutical production.  He later served as president - Schering technical operations for Schering Laboratories.  He subsequently served as senior vice president - Group C, and as president of Schering-Plough K.K., Japan. He was a Corporate Vice President  and President of Technical Operations. He is currently on the Board of Yonkers Industries, Cary, N. C., Aptuit and A-Bio and a Board Advisor at The Chao Center for Pharmaceutical Manufacturing. Mr. Nine served as the acting CEO for A-Bio Pharma at its initiation phase.

 

 

Professor Daniel Wang holds BS and PhD degrees in Chemical Engineering and an MS degree in Biochemical Engineering. He is an Institute Professor of Chemical Engineering at the Massachusetts Institute of Technology and a Temasek Professor at the National University of Singapore.  For more than 20 years, Professor Wang has held various positions and chairmanships in a number of technology organizations in US, Switzerland, Israel, China and Hong Kong. He is noted for his research in the fields of biotechnology and bioengineering and has served on many editorial boards, having contributed over 200 articles in journals relating to biotechnology, bioengineering and chemical engineering and authored or co-authored a number of books. He is the recipient of many awards and holds an Honorary Doctorate in Engineering from Hong Kong University of Science and Technology.